The widening losses and lack of revenue confirm GHRS remains a high-risk pre-revenue biotech. The FDA clinical hold lift is a positive catalyst, but the company still faces significant regulatory and commercial hurdles. The two recent equity offerings have diluted existing shareholders substantially. Monitor for updates on the pivotal trial initiation and any DEA scheduling progress for mebufotenin.
Price Chart
Executive Summary
GH Research filed its 2025 annual report (Form 20-F) via a 6-K, revealing a net loss of $48.3 million (up from $39.0 million in 2024), an accumulated deficit of $154.4 million, and no revenue. The FDA lifted the clinical hold on GH001's IND in December 2025, allowing the company to plan a pivotal trial in 2026. The filing also confirms a February 2025 public offering of 10 million shares at $15.00, raising $139.8 million net, and a subsequent April 2026 follow-on offering of 6.5 million shares at $18.00, raising ~$111.2 million net.
Key Facts
- Net loss widened to $48.3 million in FY2025 from $39.0 million in FY2024.
- Accumulated deficit reached $154.4 million as of December 31, 2025.
- No revenue generated; company remains pre-commercial.
- FDA lifted clinical hold on GH001 IND in December 2025; pivotal trial expected to start in 2026.
- Cash, cash equivalents, and marketable securities totaled $280.7 million as of Dec 31, 2025.
- Completed a public offering of 10M shares at $15.00 in Feb 2025, netting $139.8 million.
- A subsequent follow-on offering of 6,527,779 shares at $18.00 closed in April 2026, raising ~$111.2 million net.
- Chairman Florian Schnharting beneficially owns 23.9% of outstanding shares.
- Total shares outstanding increased from 52.0M (Dec 2024) to 62.0M (Dec 2025), plus 6.5M from the April 2026 offering.
- Company expects to be a PFIC for 2025 and likely 2026, with adverse U.S. tax consequences for investors.
Financial Impact
Net loss of $48.3 million in FY2025, accumulated deficit of $154.4 million. Cash burn from operations was $43.6 million. Two equity offerings in 2025/2026 raised a combined ~$251 million, causing dilution of ~26% from Dec 2024 levels.
Risk Factors
- Continued operating losses and no near-term revenue visibility.
- Significant shareholder dilution from two equity offerings in 2025/2026.
- Regulatory and commercial risks: GH001/002 are novel, Schedule I substances requiring DEA rescheduling.
- Dependence on successful pivotal trial outcomes and FDA/EMA approvals.
- PFIC status may deter U.S. institutional investors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001140361-26-021079 |
| Document: ef20072863_ex99-1.htm | 0001140361-26-021079 |
| Document: ef20072863_6k.htm | 0001140361-26-021079 |
| Document: 0001140361-26-021079-index-headers.html | 0001140361-26-021079 |
| Document: 0001140361-26-021079-index.html | 0001140361-26-021079 |
| Document: 0001140361-26-021079.txt | 0001140361-26-021079 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $21.11 $18.15 | ▼ −14.02% | ▼ −12.05% | $19.18 (−9.14%) |
Sep 11, 2026 6w ago | 6-K | $27.20 $28.26 | ▲ +3.90% | ▲ +4.12% | $19.18 (−29.49%) |
Aug 6, 2026 11w ago | 6-K | $30.64 $28.19 | ▼ −8.00% | ▼ −9.21% | $19.18 (−37.40%) |
May 14, 2026 23w ago | 424B5 | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $19.18 (+13.64%) |
May 14, 2026 23w ago | 6-K | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $19.18 (−13.64%) |
May 14, 2026 23w ago | Press Release | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $19.18 (−13.64%) |
May 13, 2026 23w ago | 6-K | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $19.18 (+13.64%) |
Apr 29, 2026 25w ago | 424B5 | $19.16 $21.28 | ▼ −11.06% | ▼ −7.95% | $19.18 (−0.10%) |
Apr 1, 2026 29w ago | 3 | $14.57 $15.72 | ▲ +7.89% | ▲ +4.27% | $19.18 (+31.64%) |
Mar 25, 2026 30w ago | Press Release | $13.65 $14.72 | ▲ +7.84% | ▲ +8.08% | $19.18 (+40.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers